Abstract-Background: Estrogen loss has been related to higher incidence of stroke in postmenopausal women, but randomized trials have demonstrated an increased risk of stroke in women receiving hormone replacement therapy (HRT). Objective: To assess the relationship between exposure to endogenous ovarian hormones and the risk of noncardioembolic ischemic stroke. Methods: We conducted a multicenter, age-matched, case-control study in postmenopausal women (case: nonembolic ischemic stroke; control: no stroke) comparing duration of ovarian activity or lifetime estrogen exposure, which was defined as age at menarche to age at menopause. Embolic cardiopathy and unreliable gynecologic data were exclusion criteria. Cardiovascular disease risk factors were recorded. The relationships of the principal variables to the risk of stroke were assessed using a conditional logistic regression analysis. Results: There were 430 cases and 905 controls in the study. In the multivariate analysis, hypertension (odds ratio [OR]: 2.73; 95% CI: 2.09 to 3.58; p Ͻ 0.0001), diabetes (OR: 3.38; 95% CI: 2.53 to 4.52; p Ͻ 0.0001), hyperlipidemia (OR: 1.31; 95% CI: 1.01 to 1.7; p ϭ 0.045), lifespan of ovarian activity Ͻ34 years (OR: 1.51; 95% CI: 1.13 to 2.03; p ϭ 0.005), and menarche at Ͻ13 years of age (OR 1.49; 95% CI: 1.15 to 1.92; p ϭ 0.002) were independently related to an increased risk of stroke. Obesity (OR: 0.73; 95% CI: 0.56 to 0.95; p ϭ 0.021) was related to a lower risk of stroke. Conclusions: Longer lifetime exposure to ovarian estrogens may protect against noncardioembolic ischemic stroke. However, a very early age of exposure onset could be disadvantageous. NEUROLOGY 2007;68:33-38 Ischemic stroke of atherothrombotic origin is uncommon in premenopausal women. This has been related to a protective effect exerted by ovarian hormones against atherosclerosis.
Ischemic stroke of atherothrombotic origin is uncommon in premenopausal women. This has been related to a protective effect exerted by ovarian hormones against atherosclerosis. [1] [2] [3] [4] [5] [6] [7] Various regimes of hormone replacement therapy (HRT) have been evaluated in the hope of restoring protection against cardiovascular disease (CVD). Studies assessing the effects of HRT on carotid atherosclerosis [8] [9] [10] [11] [12] and on risk of stroke [13] [14] [15] [16] have shown conflicting data, with results ranging from a reduction to an increase in risk attributable to HRT. Randomized placebocontrolled clinical trials and two recent metaanalyses have indicated that HRT has no demonstrable beneficial effect, whereas the absolute risk of ischemic stroke is increased, both in healthy postmenopausal women and in women with prior stroke. [17] [18] [19] [20] [21] [22] These results have led to the recommendation that HRT should not be implemented for the primary or secondary prevention of stroke or CVD in postmenopausal women. 7, 23 However, the real effect of endogenous estrogens on stroke remains unanswered because there are important differences between the effects of physiologic endogenous estrogens and exogenous hormones administered after menopause. Our hypothesis is that if endogenous estrogens were protective, a longer reproductive period or ovarian activity (estrogenic lifetime-an indirect indicator of exposure to endogenous estrogens) would be associated with a lower risk of nonembolic ischemic stroke. Hence, we examined the duration of ovarian activity, defined as the age of its commencement (menarche) up until its conclusion (menopause), in relation to the risk of suffering a stroke.
Methods. Study design, population, and data collection.
The PIVE study (Protección frente al Ictus en función de la Vida Estrogénica; "Protection against stroke as a function of estrogenic lifetime") is a multicenter, age-matched case-control study conducted in 18 hospitals.
Cases were postmenopausal women who had suffered at least one episode of symptomatic ischemic stroke or TIA of noncardioembolic origin (atherothrombotic, lacunar, or of unknown cause despite extensive investigation). All patients underwent a complete neurologic evaluation, including cranial CT or MRI, carotid Doppler ultrasonography, and echocardiography for diagnosis of stroke subtype and cause. Controls were age-matched postmeno-pausal women who had not suffered a stroke and were drawn from among the outpatient clinics of the same hospitals from which the cases were recruited. Assessments in controls sought evidence of various neurologic diseases (migraine, other types of headache, movement disorders, neuromuscular disorders, epilepsy). Patients with diagnosis of dementia or any type of memory loss and women suffering from any gynecologic disease or breast cancer were not considered for inclusion in the study. Each woman was interviewed by the attending physician according to a standardized questionnaire. The information collected included the principal variables of age at menarche and at menopause (defined as the age at definitive cessation of menstruation, whether natural or resulting from surgical double oophorectomy). The duration of estrogenic lifetime, or ovarian activity, was calculated as the number of years between menarche and menopause. The history of oral contraceptive or HRT use was recorded. The questionnaire also registered personal history of the following risk factors for stroke: hypertension, diabetes, or hyperlipidemia according to established criteria [24] [25] [26] ; cardiovascular disease (ischemic heart disease, myocardial infarction, valve disease, atrial fibrillation); tobacco use (number of cigarettes per day); alcohol consumption (g/d); obesity (defined as body mass index Ͼ 30 kg/m 2 ); migraine according to diagnostic criteria of the International Classification of Headache Disorders, first edition 27 ; and peripheral arterial disease (defined as symptoms consistent with intermittent claudication or Doppler ultrasound diagnosis of arterial disease of the lower limbs with an ankle-brachial blood pressure index Ͻ0.9. All cases were examined by a neurologist who diagnosed the cause of stroke according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria 28 and classified the condition using the Oxfordshire Community Stroke Project (OCSP) classification. 29 First-stroke date was recorded as well as severity, which was defined according to the Canadian Neurological Scale. 30 Functional status was graded according to the modified Rankin scale. 31 Exclusion criteria were a previous history of atrial fibrillation or any other cardiac source of embolism (such as valve disease) and unreliability of reported age at menarche and age at menopause (hysterectomy without double oophorectomy, which would impede assessment of menopause defined as the cessation of menstruation-ovarian activity could continue but without menstruation; hesitancy in self-reporting of data; absence of a documented gynecologic history).
Informed consent to participate in the study was obtained from all cases as well as controls. The study was approved by the ethics committees of the participating hospitals on the understanding that all data would be coded and patient anonymity guaranteed.
Sample and statistical analysis. Between January 2001 and March 2004, 1,335 women fulfilling the inclusion criteria and with none of the exclusion criteria and who had reliable data on age at menopause and at menarche (as described above) were enrolled in the study. There were 430 cases and 905 age-matched controls consecutively recruited from each participating hospital. The control-to-case ratio was 2:1 to improve the power of the study.
Principal variables were categorized according to quartiles of distribution in the study sample as follows: age at menarche Ͻ12, 12, 13, Ͼ14; age at menopause Ͻ47, 47 to 50, 51 to 53, Ͼ53; duration of ovary activity: Ͻ34, 34 to 36, 37 to 40, Ͼ40 years. The lowest quartile of each variable was used as a reference for the analysis. Categorized variables are presented with their distributions of frequencies. The prevalence of principal variables and of the covariates were calculated in cases and controls. Because age is a confounding factor, we performed a stratified paired analysis to eliminate the effect of age; each case was compared with the controls of the same age. Univariate analyses were performed (McNemar test). The magnitude of associations were evaluated with the paired odds ratio (OR) and the corresponding 95% CI. A model of conditional logistic regression analysis was used to evaluate the principal variables' relationship with stroke after adjustment for the covariates that had statistical value of p Ͻ 0.15 in the univariate analysis. Adjusted paired ORs with their corresponding 95% CI values are presented. Null hypothesis was rejected with a type I (␣) error Ͻ 0.05. Missing data were not replaced. All analyses were performed with the SPSS 12.0 for Windows and the SAS 8.0 statistical packages.
Results. The mean age of participants was 68.9 years (range: 46 to 93). Of the 430 cases, 30% had had TIA and 70% had suffered ischemic strokes (6.3% total anterior circulation infarct, 20.7% partial anterior circulation infarct, 30.8% lacunar infarct, and 12.2% posterior circulation infarct). With respect to cause, 50.7% of cases were classified as atherothrombotic, 29.3% as lacunar, 19.8% as undetermined despite extensive clinical workup, and 0.2% were attributed to uncommon causes; for instance, one patient was diagnosed as a carrier of the prothrombin gene polymorphism G20210A. There were no patients with cardioembolic stroke, and none of those classified as "undetermined" were attributable to coexistence of cardioembolic sources of other origins, because these were among the exclusion criteria at recruitment.
Distribution of risk factors among controls and cases and the univariate analysis of their associations with stroke (OR and 95% CI) are summarized in table 1. Hypertension and diabetes were more prevalent among cases. Migraine was more frequent among controls than among cases. Table 2 summarizes the distribution of frequencies by quartiles of the principal variable duration of estrogenic lifetime, age at menarche, and age at menopause, together with the univariate analysis of the association of these factors with stroke (paired OR and 95% CI). Longer estrogenic lifetime was associated with a lower risk of stroke, that is, lower OR for having a stroke associated with a longer duration of ovarian activity. Grouping the second, third, and fourth quartiles of estrogenic lifetime, and compared with the lowest (first) quartile, a shorter duration of ovarian activity Ͻ34 years was associated with higher risk of suffering a stroke (OR: 1.4; 95% CI: 1.07 to 1.82; p ϭ 0.01). Menarche between the ages of 13 and 14 seemed to be related to lower risk of stroke. Grouping the quartiles on the basis of their behavior with respect to the effect on stroke risk, and using the median age at onset of menarche as reference, the results indicated that menarche at age Ͻ13 years was associated with an increased risk of stroke (OR: 1.64; 95% CI: 1.11 to 2.17; p ϭ 0.004). Age at menopause was not associated with stroke. Duration of estrogen exposure was not related to the timing of first stroke.
The results of the conditional logistic regression analysis performed to investigate the variables associated with stroke, after adjustment for the covariates, are presented in table 3. Length of reproductive life Ͻ34 years remained an independent hazard factor for stroke as well as age at menarche Ͻ13 years. Hypertension, diabetes, and hyperlipidemia were independently associated with stroke, but smoking was not. Obesity was associated with a lower risk of stroke.
There were no associations found between estrogen exposure and specific stroke subtypes, as defined by the TOAST or OCSP classifications.
Discussion. In this case-control study, a shorter duration of ovarian activity (or estrogenic lifetime) was independently associated with a higher risk of having a noncardioembolic ischemic stroke, after adjustment for other cardiovascular disease risk factors; that is, there was a 51% higher risk for lifetime of estrogen exposure of Ͻ34 years. This finding supports the hypothesis proposed by previous observational studies that exposure to endogenous estrogens protects against ischemic stroke of noncardioembolic origin. However, an earlier age at menarche was associated with an increased risk of stroke. The findings suggest that a sufficient time of exposure to ovarian estrogens is necessary for there to be a protective effect, but if this exposure had begun early, the effects would have been deleterious. However, the timing of cessation of ovarian activity (after adjustment for confounding covariates) seems to be less important; the age at menopause does not seem to have any effect on the risk of stroke. The deleterious effect of early menarche can be explained on the basis of the high accumulated dose of estrogens. This can be equated to the high doses of external estrogens when used as oral contraceptives 32 or as HRT, [17] [18] [19] [20] [21] [22] which is known to augment the risk of stroke. Also, the effects of the estrogenic activity can vary depending on the physiology of the woman at her specific age; deleterious outcomes can occur in an organism that is not physiologically prepared for such activity. This can also explain the HRT estrogens having deleterious effects when administered in postmenopausal women. As has been shown in randomized trials, [17] [18] [19] [20] [21] [22] estrogens in HRT are usually given later on in a woman's life and for a time course that is shorter than the woman's natural exposure during her lifetime. Also, hormonal therapy with estrogen is administered at nonphysiologic, noncyclic doses and, in many cases, in combination with progestin, with the intention of reducing the risk of endometrial cancer. Possibly, the protective effects of estrogen could be lost when plasma levels are maintained beyond the physiologic range after exogenous administration, at later ages in postmenopausal women, or if exposure to endogenous estrogens begins at a very early age. This could be explained by alteration of the equilibrium between activation of the two known types of estrogen receptors that could have different antiatherogenic and neuroprotective capabilities. [2] [3] [4] 33 Methodologic considerations also may be evoked to explain the lack of beneficial effects of HRT in randomized trials. None of the trials distinguished between the etiologic subtypes of ischemic stroke, or the specific risk for each type, in relation to HRT. [17] [18] [19] [20] [21] [22] If estrogen protects against atherosclerosis, then atherothrombotic stroke and, possibly, lacunar infarction may be prevented, but not cardioembolic stroke. Including stroke of cardiac origin in the analysis could mask a possible protective effect against atherosclerosis and atherothrombotic stroke. Our study specifically excluded cardioembolic stroke as well as women with potential sources of cardiac embolism. As such, our conclusions are applicable to those subtypes of ischemic stroke that are specifically attributable to arterial disease.
A possible association between stroke and previous use of oral contraceptives or HRT cannot be analyzed in this study because only a few women within the study population fell into these categories.
Hypertension, diabetes, and hyperlipidemia were independently associated with stroke, but tobacco smoking was not. This could be explained by the very low prevalence of smoking among the women in our study sample. Obesity, however, seemed to be associated with a lower risk of stroke, even though it was documented as a risk factor. 34 The observation may be in accord with the protective effect of estrogen suggested by our study, because fat is a source for extragonadal synthesis of estrogen, 35 and, as such, overweight/obese women would have a higher amount of circulating estrogen once ovarian activity had ceased. This would result in prolonging the proposed protective effect, even after menopause. The higher prevalence of migraine among control subjects is probably attributable to inclusion bias because the control subjects were recruited from the outpatient clinics, where migraine is a common clinical presentation. Hence, migraine was not included in the multivariate statistical analysis.
A relationship between the duration of reproductive life and cardiovascular risk has been suggested previously; the majority of data refer to risk of coronary heart disease. Most investigations only examined the relationship with age at menopause, not with age at menarche. Risk of coronary heart disease and cardiovascular mortality seem to be lower among women with a higher age at menopause, [36] [37] [38] [39] although in one study, 39 this association was only significant among current smokers and, as the authors suggest, this could be explained on the basis of smoking being a residual confounding variable. One of the studies 38 observed a reduction in cardiovascular mortality among women with longer exposure to endogenous estrogen for Ͼ18 years. Age at menarche, on the contrary, was not significantly associated with coronary heart disease in a prospective study. 40 There are even less data on the risk of stroke in relation to the duration of reproductive lifetime. Only one study 41 indicated an increased risk among women with menopause at age Ͻ40 years, whereas two other studies 38, 39 did not support any such relationship. Again, these studies did not separately evaluate the etiologic subtypes of ischemic stroke. Another study 42 did not find any relationship between age at menopause and stroke mortality. There have not been any studies investigating the risk of noncardioembolic ischemic stroke in relation to age at menarche, age at menopause, and duration of reproductive lifetime. Our present study, on the other hand, clearly establishes a protective relationship between duration of exposure to endogenous estrogens and the risk of suffering a noncardioembolic ischemic stroke.
Some methodologic issues should be considered. First, it can be argued that misclassification may have occurred as a result of errors in patients' recall of age at menarche and age at menopause. We tried to preempt such bias by including only women who were able to provide consistent reports without any hesitancy or for whom a documented gynecologic history was available. There have been reports [43] [44] [45] [46] on the validity and reproducibility of self-reported age at menarche and age at menopause. Reliability of self-reported age at menarche is about 75% 45 ; for age at menopause, this ranges between 72% and 75% and 82%. 39, [44] [45] [46] Validity and reproducibility of data depend mainly on the subject's educational level and age when interviewed. Mean age for the present study population was 68.3 years, but educational levels in these women had not been noted. However, the consequence of any misclassification on our part would be that the risk estimates could be biased toward the null hypothesis (i.e., underestimated) when self-reported data are used. 44 This implies that in a study in which an increased risk for disease with increasing age at menopause is observed, the real risk may be even higher. Similarly, when a decreased risk for disease is observed with increasing age at menopause, the real risk may be even lower. These findings lend support to the internal reliability of our data. Because the control subjects had been recruited from neurology clinics, this can result in distributions of some risk factors being different from what is observed in the general population and more closely resembling the distributions among the cases. However, this also would result in an underestimation of the differences observed. Finally, the participants were recruited from rural as well as urban areas, with a wide geographic distribution. As such, the influence of geographic and cultural differences would be minimized.
A further criticism could be that a case-control study would not define the real effect of endogenous estrogen on the risk of stroke with as much accuracy as a prospective cohort study observed for an extended period of time. This type of study, although desirable, is not feasible because of cost. Such a study would involve a cohort of women being observed for the course of their whole reproductive life and beyond menopause to investigate the incidence of stroke in relation to exposure to endogenous estrogen. A case-control study is not only much easier to conduct, it is a realistic way to assess differences in age at menarche, age at menopause, and duration of ovarian activity between women who have and have not suffered a stroke. The data generated are sufficiently reliable to highlight associations between these variables, enabling further estimation of their protective, deleterious, or null effect regarding susceptibility to stroke. These data may help identify those women at higher risk of stroke after menopause.
